In early 2025, ASAP offered two open, competitive funding opportunities for the research community to provide additional capital to spur discovery for Parkinson’s disease (PD) research
Scientific Track: Focus on supporting high-priority projects to dissect the mechanisms that contribute to PD heterogeneity.
Funding Scope
Funds provided by ASAP may be used for scientific and technical personnel, supplies, and standard equipment needs directly related to the successful execution of the proposed scope of work. ASAP funds may not be used for laboratory or facility renovation. As you prepare your budget, please remember that the maximum total amount requested per team per year is $2 million USD, inclusive of indirect costs.
The maximum total amount requested for the project is $6 million USD, inclusive of a 15% indirect rate applied to the team’s direct costs.
Proposals must address ASAP’s high-priority research areas, such as:
Neuro-immune interactions
Circuitry & brain-body interactions (especially non-motor symptoms)
Functional genomics
Aging, clearance mechanisms, or alpha-synuclein seeding in PD
Must propose a team of 3–5 PIs across 2–5 institutions, including:
A lead PI in an independent faculty position
At least one early-career investigator
Multidisciplinary representation .
Projects require a strong link to human datasets (e.g., clinical cohorts, PPMI).
Purely tool-development or motor-focused circuit studies are NOT in scope .
Funding is up to US $3M/year for up to 3 years.
Proposals must include clear aims, deliverables, and timelines compatible with ASAP’s collaborative framework
ASAP enforces strict open science policies:
Preprint posting
Public data/code sharing
Use of ASAP Hub or CRN Cloud resources.
Scientific Track: hypothesis-driven disease mechanism studies (as above).
Technical Track: tool/resource creation with teams combining PD biology, toolmanship, and distribution capabilities
Teams must be international, cross-disciplinary and integrate early-career researchers to foster collaboration and pipeline development .
📋 Summary Table
Predictor | What You Should Deliver |
---|---|
ASAP scientific fit | Align with ASAP’s focus areas (e.g., neuro-immune, aging) |
Collaborative team structure | 3–5 PIs, ≥2 institutions, early-career PI included |
Human PD connection | Use human data cohorts, avoid basic tool-only projects |
Feasible, milestone-driven plan | Structured goals with timeline, ready for $3M/year scale |
Open science enforcement | Preprints posted, data & code shared openly |
Track specificity | Scientific vs Technical track with correct setup |
International & multidisciplinary | Combine global partners, disciplines, and ECI mentoring |
🛠 Bonus Tips
Start with:
A strong Letter of Intent (due March 20, 2025)
Follow ASAP’s two-phase selection: LOI → full proposal → interviews (~January 2026)
Embrace ASAP’s collaborative culture: Open science, consortium meetings, preprints, data sharing .
Define roles and responsibilities early, including project management and ECI integration.
Engage human PD resources (PPMI, global genetics, patient cohorts) in your design.
Ensure tool distribution feasibility for Technical Track (e.g., CRO partnerships, click-to-order mechanism)
Institutional Eligibility
● Type – Applications may be submitted by public and private non-profit entities, such as universities, colleges, hospitals, laboratories, units of state and local governments, as well as eligible agencies of the federal government. For-profit entities are also encouraged to apply provided that the applicant holds a Senior Scientist position or equivalent and agrees to comply with all outlined policies & requirements including (but not limited to) the ASAP Open Science policy.
● Geographic Focus – Applications may be submitted by U.S. and foreign entities.
● Submitting Institution – The Coordinating Lead PI must be affiliated with the institution submitting the application and grant funds will be awarded to that institution, which will take responsibility for distributing funds to the institutions of the other members of the collaboration.
Core Leadership Eligibility
● Core Leadership – Each Team must consist of a minimum of two (2) to a maximum of five (5) PIs. A Coordinating Lead PI must be appointed for each Team, who will be responsible for overall project management and reporting to ASAP/MJFF staff throughout the lifecycle of each program. A Core/Repository Co-Investigator must be appointed for each Team, who will be responsible for commercialization of the resulting preclinical reagents/models. Team structure and management is discussed in further detail below.
● Disciplines Represented – There must be at least two (2) different research disciplines represented on each Team.
● Institutions – There must be a minimum of two (2), but no more than five (5) participating institutions represented by the Team. An absolute maximum of six (6) participating institutions as referenced in the exception above is applicable.
● Degree – All Core Leadership must hold a doctorate, such as a PhD, MD, or equivalent degree. The exception may be the Core/Repository Co-Investigator but this individual must be authorized to act on behalf of their Institution within this program.
● Appointment – The Coordinating Lead PI must have an academic appointment and be in an independent faculty position or equivalent. A Coordinating Lead PI from the private sector must hold a Senior Scientist position or equivalent. All other Core Leadership must be in an independent faculty position or equivalent. If applying from the private sector, the applicant must hold a Senior Scientist position or equivalent.
● Time Allocation – All Core Leadership except for the Core/Repository Co-Investigator must commit to a minimum allocation of 0.25 (25%) of their time and effort.
Ineligibility This RFA will not provide funding for the following types of projects:
● Projects to generate preclinical tools/models for targets outside the list provided by ASAP or projects that will not be generating preclinical tools/models.
● Projects performing hypothesis-driven research rather than generating and validating novel preclinical tools/models.
● Projects generating preclinical reagents/models that cannot or will not be rapidly shared with the research community through commercial mechanisms.
Sponsor Institute/Organizations: Aligning Science Across Parkinson’s (ASAP)
Sponsor Type: Corporate/Non-Profit
Address: 5425 Wisconsin Ave #600, Chevy Chase, MD 20815
Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.
Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.
Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.
Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.
Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.
Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.
Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.
Aug 07, 2025
$9,000,000
Affiliation: Aligning Science Across Parkinson’s (ASAP)
Address: 5425 Wisconsin Ave #600, Chevy Chase, MD 20815
Website URL: https://parkinsonsroadmap.org/funding-opportunities/#
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.